Biotechnology company, AquaBounty Technologies, Inc. has received regulatory approval in Canada for the sale of its GM salmon which it says is an important step towards commercialisation.
AquaBounty Technologies has announced that the US Food and Drug Administration (FDA) had approved its new animal drug application for the production, sale and consumption of its AquaAdvantage Salmon.
Environmental groups are in dispute with the Canadian government over the manufacturing of genetically modified salmon in the country.
In the midst of the ongoing debate in the US on the introduction of genetically modified transgenic salmon, Marine Harvest and WWF-Norway have said that if GM salmon is approved for human consumption then it must be labelled as such.
AquaBounty Technologies is now able to produce its AquAdvantage Salmon (AAS) on a commercial scale after being approved by Environment Canada.
America’s AquaBounty Technologies has announced that the FDA’s Environmental Assessment of its AquAdvantage Salmon treatment is due for publication, a significant part of the FDA approval process for the product.
Actions for investment and financing opportunities together with the day to day practicalities of ru... Read more
Lilja Alfreðsdóttir, the Minister of Education, Science and Culture in Iceland announced the winners... Read more
February 2018 Fareham UK - Mercator Media Ltd, the international, market-leading B2B marine media bu... Read more